Proteogenix
|
WikiDoc Resources for Proteogenix |
|
Articles |
|---|
|
Most recent articles on Proteogenix Most cited articles on Proteogenix |
|
Media |
|
Powerpoint slides on Proteogenix |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Proteogenix at Clinical Trials.gov Clinical Trials on Proteogenix at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Proteogenix
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Proteogenix Discussion groups on Proteogenix Patient Handouts on Proteogenix Directions to Hospitals Treating Proteogenix Risk calculators and risk factors for Proteogenix
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Proteogenix |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Proteogenix is a corporation based in Portland, Oregon, United States, that develops and markets biomarker diagnostic tests for the detection of life-threatening pregnancy-related conditions. Proteogenix is currently developing non-invasive protein biomarker screening tests for intra-amniotic infection, premature birth, and Down syndrome, which combined cause 175,000 premature births each year in the United States alone.[1]
References
- ↑ "ProteoGenix News from The BioSpace Beat". Biospace.com. September 29, 2004.